MedTrace Logo

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

NCT01543503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1225

Last updated 2016-02-10

Study results available
· View outcomes & findings →

Summary

This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy. Data will be collected for 52 weeks.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Argentina
  • Belgium
  • Colombia
  • Ecuador
  • Germany
  • Greece
  • Guatemala
  • Italy
  • Mexico
  • Panama
  • Portugal
  • Spain
  • Switzerland
  • Ukraine
  • United Kingdom
  • Uruguay

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543503 on ClinicalTrials.gov